{"id":"W2767242523","doi":"10.1093/neuonc/nox168.065","title":"ACTR-78. TAMIGA: A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CONTINUOUS BEVACIZUMAB THROUGH MULTIPLE LINES OF TREATMENT FOR GLIOBLASTOMA","year":2017,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Temozolomide; Lomustine; Internal medicine; Clinical endpoint; Placebo; Randomization; Adverse effect; Progression-free survival; Oncology; Phases of clinical research; Randomized controlled trial; Chemotherapy; Surgery; Cyclophosphamide; Vincristine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001223397,0.001647815,0.001806523,0.0005880276,0.000347995,0.0007024104,0.001069028,0.001248281,0.004510495],"category_scores_gemma":[0.0008365059,0.0006150154,0.001008693,0.0004188193,0.0008606985,0.0006229422,0.0003155196,0.00231034,0.001148753],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007060398,"about_ca_system_score_gemma":0.001354911,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001128626,"about_ca_topic_score_gemma":0.003282835,"domain_scores_codex":[0.9995971,0.0001938919,0.00002273972,0.00007014368,0.00004263495,0.00007348366],"domain_scores_gemma":[0.9994817,0.00008083371,0.0001279963,0.00003637164,0.0000274195,0.0002456958],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8248196,0.04013932,0.003021759,0.001091044,0.001106714,0.0002854519,0.000164708,0.0009934511,0.04612334,0.000324161,0.004003013,0.07792742],"study_design_scores_gemma":[0.779232,0.2122654,0.003741772,0.00002486915,0.0003903653,0.0001896495,0.00002033058,0.0005038154,0.002142286,0.00008032814,0.001390761,0.00001845089],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899961,0.003483859,0.0005347818,0.0003968236,0.0001554826,0.002752084,0.001000986,0.0001883461,0.00149158],"genre_scores_gemma":[0.9864244,0.002630601,0.001724338,0.0006499996,0.0002819553,0.0042184,0.001699816,0.00004375807,0.002326775],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004510495,"threshold_uncertainty_score":0.01508909,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0750547322509103,"score_gpt":0.4181039271747186,"score_spread":0.3430491949238083,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}